The conference will cover all aspects of HD drug development, including current and future biomarkers, novel HD therapeutic approaches, the new HD Integrated Staging System, updates on clinical trials including GENERATION HD1, and other presentations informing our understanding of HD pathophysiology.
Join us for a unique opportunity to bring together academic and private sites outside the realm of specific Alzheimer’s disease (AD) and Parkinson’s disease (PD) clinical trials. Meet and network with leadership from clinical trial sites across North America, global pharma sponsors, and many partners in AD and PD clinical trial development. Hear from world-class sites and partners on current development barriers, best practices and strategies and engage in the future of clinical trials.
Attending this conference gives you the opportunity to engage with representatives from research sites, to hear their experiences and feedback first-hand outside the scope of working with them directly on a clinical trial. Attendees may glean site perspectives, research trends, common study barriers and innovative solutions, and share how sponsors can be more responsive to sites to increase success in recruitment and enrolment. We have received positive feedback from industry partners who have attended in the past regarding the value they gained in this “out of office” encounter opportunity.